ArticleCurrent oncology (Toronto, Ont.)2023

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.

Martin Rupp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.